3 Sep 2020 07:00
Silence Therapeutics to Participate in Virtual U.S. Investor Conferences in September
3 September 2020
LONDON, Silence Therapeutics plc (LON: SLN) ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, today announces that Company management will present a Company overview and host one-on-one meetings during four upcoming virtual investor conferences, details of which can be found below:
Wall Street Investor Forum Virtual Conference
Date: | Thursday, September 10, 2020 | |
Time: | 12:00 pm EDT (17:00 BST) |
H.C. Wainwright 22nd Annual Global Investment Conference
Date: | Tuesday, September 15, 2020 | |
Time: | 11:30 am EDT (16:30 BST) |
Morgan Stanley 18th Annual Global Healthcare Conference
Date: | Thursday, September 17, 2020 | |
Time: | 12:30 pm EDT (17:30 BST) |
Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Date: | Tuesday, September 22, 2020 | |
Time: | 10:00 am EDT (15:00 BST) |
Live webcasts of the Company's presentations can be accessed via the Investors section of the Company's website at www.silence-therapeutics.com. An archived replay of the webcasts will be available for 60 days on the Company's website after the conference.
For more information, please contact:
Silence Therapeutics plc Iain Ross, Executive Chairman Rob Quinn, Chief Financial Officer
| Tel: +44 (0)20 3457 6900 |
Investec (Nominated Adviser and Broker) Daniel Adams/Gary Clarence
| Tel: +44 (0) 20 7597 5970 |
European IR Consilium Strategic Communications Mary-Jane Elliott/Chris Welsh/Angela Gray silencetherapeutics@consilium-comms.com
| Tel: +44 (0) 20 3709 5700 |
U.S. IR Westwicke Peter Vozzo peter.vozzo@westwicke.com | Tel: +1 (443) 213-0505 |
About Silence Therapeutics plc
Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-associated proteins. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases. The Company has secured high value research and collaboration agreements with AstraZeneca, Mallinckrodt Pharmaceuticals and Takeda. For more information, please visit: https://www.silence-therapeutics.com/